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Abstract The purpose of the study was to evaluate the long-
term outcome of minor salivary and mucous gland (MiSG) ade-
noid cystic carcinoma (ACC) of the head and neck and to com-
pare the results with earlier reports including our recently pub-
lished series on major salivary gland (MaSG) ACC. The study
comprised 68 MiSG ACCs operated during 1974–2012 at the
Helsinki University Hospital, Helsinki, Finland. Medical records
and histological samples were reviewed. Our previously pub-
lished cohort comprising 54 MaSG ACCs during the years from
1974 to 2009 was used for comparison. The most common lo-
cations were the oral cavity and sinonasal cavities. Most patients
presented stages IV (33.8%) and I (23.5%) disease. Primary
treatment with curative intent, mainly surgery, was offered for
64 patients. Thirty-three (51.6%) of these patients developed a
disease recurrence and 22 (66.7%) patients in less than 5 years.
The difference in the length of recurrence-free time (<5 vs.
>5 years) had an impact on OS and DSS (p < 0.001) showing
worse prognosis for the earlier recurring group. T classes 2–4
(p = 0.005, p < 0.001, and p = 0.001, respectively) and stages
II–IV (p = 0.019, p < 0.001, and p = 0.002, respectively) were
associated with worse OS, DSS, and DFS. MiSG ACC had a
similar long-term survival compared to MaSG ACC. Patients
with stage I MiSG ACC seem to carry a favourable prognosis
compared with those with stages II, III, and IV tumours. It is thus
noteworthy that stage II tumours represent a truly advanced dis-
ease entity warranting a more aggressive treatment approach.
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Introduction
Adenoid cystic carcinoma (ACC) is a salivary and mucous
glandmalignancywith poor long-term prognosis. It has a slow
but persistent clinical course and diagnosis is often made at the
advanced stage with occurrence of perineural invasion. ACC
has a distinctive tendency to develop local and distant metas-
tases at a late stage, even after one or two decades. According
to our previous study on major salivary gland (MaSG) ACC,
most distant metastases appear within a 10-year period [1].
The 2017World Health Organization (WHO) classification
of salivary gland tumours comprises 19 malignant entities.
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ACC is denoted as the second most common malignancy [2].
Some nationwide studies from Finland, Denmark, and
Pakistan, however, have reported that the most common sali-
vary gland cancer in those countries is ACC [3–5].
The primary treatment for ACC is radical surgery with
possible postoperative radiotherapy [6]. Chemotherapy is
used in advanced, recurrent, or metastatic ACC. However,
effective chemotherapeutic agents are lacking [6]. In the fu-
ture, cumulative knowledge on genomic alterations of ACC
may lead to novel chemotherapeutic treatments [7].
About 70% of all ACC cases originate in salivary glands.
Minor salivary glands (MiSGs) are more often involved than
MaSGs [8, 9]. ACC of MiSGs represents 2–4% of all head
and neck malignancies [10, 11]. These typically appear in
areas with salivary or mucous glands (i.e., in the oral cavity,
oropharynx, sinonasal area, and upper respiratory tract) [12].
Most previous studies have included all cases of salivary
gland ACCs, and only a few reports focus especially on
MiSGs [9, 11, 13–17]. Therefore, the aim of this study was
to investigate the clinical presentation, treatment, and outcome
in the group of rarely investigated MiSG ACCs at a tertiary-
care academic referral centre during a 38-year period and to
compare the outcome to that of MaSG ACC. Moreover, our
goal was to generate whole-population information based on
regional data covering one-third of the Finnish population.
Materials and methods
We evaluated 68 patients with MiSG ACC who were treated
between 1974 and 2012 at the Department of Otolaryngology,
Head and Neck Surgery, Helsinki University Hospital,
Helsinki, Finland. The previously reported 54 patients with
MaSGACCs were operated on during 1974–2009 at the same
institution [1]. This single tertiary-care academic centre repre-
sents 1.6 million inhabitants, covering approximately one-
third of the Finnish population.
We collected data on patient characteristics, histological
parameters and clinical features of the tumour, treatment mo-
dalities, and survival outcome. Tumour size measurement was
based on histological samples or identified from medical re-
cords. In three cases where there was inadequate tumour size
information, the head and neck radiologist (S.A.) identified
sizes from MRI images. An experienced head and neck pa-
thologist (J.H.) confirmed the histopathological diagnoses
using the histopathological diagnostic criteria validated and
updated according to the WHO classification (2005) [18].
The Institutional Research Ethics Board approved the
study concept (Dnro 31/13/03/02/2010, 01 February
2010). Statistics Finland provided the dates and causes
of death. Overall survival (OS) was determined from the
interval between the end of primary treatment and the last
day of follow-up or the date of death. Disease-specific
survival (DSS) was defined as the interval between the
last day of treatment and death due to disease. Disease-
free survival (DFS) was determined as the interval be-
tween the last day of treatment and any sign of disease
recurrence. All patients had a minimum follow-up of at
least 3 years or until death.
Statistical analyses were performed using SPSS soft-
ware (version 23.0, Chicago, IL, USA). We report values
as medians with range for descriptive purposes.
Calculations for survival rate were performed using the
Kaplan-Meier method and survival functions by the log-
rank test. Univariate associations of risk factors with OS,
DSS, and DFS were analysed using Cox regression anal-
ysis. Risk factors associated (p < 0.05 in univariate anal-
ysis) with OS, DSS, or DFS were included in multivari-
able Cox regression model. The stage was not included in
the same multivariable model with T class and neck me-
tastases at presentation to avoid multicollinearity problems.
Results are expressed using hazard ratios (HR) with 95%




Table 1 shows patient and tumour characteristics of 68 pa-
tients with ACC. The current tumor, node, and metastasis
(TNM) classification did not cover the six (8.8%) tracheal
tumours. The TNM class could not be defined in four
(5.9%) cases. Table 2 presents the relationship between tu-
mour location and stage. Almost half of the tumours in the
oral cavity (n = 41) were located in the palate (n = 20), with the
hard palate being the most frequent site (n = 15).
Primary symptoms varied depending on tumour loca-
tion. The most common clinical presentations were a
lump (27.9%) and pain (17.6%). Symptom duration var-
ied from 1 to 240 months with a median of 6 months.
Three (4.4%) patients had a second malignancy at the
time of diagnosis (prostate carcinoma, chromophobic re-
nal cell carcinoma, or thyroid papillary microcarcinoma).
Preoperative investigations
The imaging methods used before treatment for most pa-
tients included computed tomography (CT) (57.8%) and
magnetic resonance imaging (MRI) (45.6%) of the head
and neck. Other examinations included chest CT scan
(30.9%), ultrasound (16.2%), fine needle aspiration
(11.8%), and positron emission tomography CT (5.9%).
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Tumour characteristics
The median tumour size was 21 mm (range, 3–100 mm). For 19
(27.9%) tumours, size determination was not possible from clin-
ical data, histopathological report, re-evaluation of the histologi-
cal specimen, or MRI and CT images. The most common histo-
pathologic growth pattern was cribriform (33.8%) followed by
tubular (22.1%) and solid (8.8%) patterns. Most of the tumours
showed a combination of growth patterns including tubular and
cribriform (19.0%), solid and cribriform (7.4%), and solid and
tubular (1.5%). Information on the growth pattern was not avail-
able in five (7.4%) cases. Tumours were classified under one
growth pattern if more than 80% of the histologic sample was
composed of that particular pattern. However, in cases with a
combination of growth patterns, a pattern with more than 30%
solid growth was classified into the solid group. Neural invasion
(perineural, intraneural, or both) was present in 39 (57.4%) tu-
mours. Information on neural invasionwas not available for eight
(11.8%) tumours.
Treatment
Most of the patients were treated with curative intent (n = 64,
94.1%). Approximately half of these patients (n = 35, 54.7%)
received surgery only as their primary treatment. A neck dissec-
tion was performed in 17 (26.6%) cases; in 14 (82.4%) patients,
the dissection was elective and in three (17.6%) patients, the
dissection was therapeutic.
Twenty-four (37.5%) patients received postoperative radio-
therapy to their primary tumour area. One (1.6%) patient received
radiotherapy onlywith curative intent. Themedian radiation dose
was 60 Gy (range, 32–70 Gy). Five (7.8%) patients received
chemotherapy as part of the oncological treatment. One patient
was lost to follow-up.
Four (5.9%) patients received palliative treatment only.
Table 1 Characteristics of 68 MiSG ACC patients and the TNM






Median age, years (range) 58 (24–88)
Tumour site
Oral cavity 41 60.3






















Table 2 ACC location and stage










Oral cavity (oc) 41 10 12 3 13 3
Palate 20 5 4 2 9
Other oc 18 4 7 1 4 2
Upper lip 3 1 1 1
Oropharynx 3 3
Nasopharynx 5 2 2 1
Paranasal sinuses 6 6
Larynx 2 1 1
Oesophagus 1 1
Ear 4 2 1 1
N/A not available
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Outcome
Figure 1 shows a flowchart of the presentation of patients with
metastatic disease across various sites at diagnosis and during
follow-up. In 22 (66.7%) patients, the first appearance of their
metastatic disease occurred within 5 years after treatment;
nine (27.3%) patients later than 5 years after treatment.
Patients with early metastatic disease had poorer OS and
DSS than patients with no metastases during follow-up
(Table 3) (Fig. 2). Among the patients treated with curative
intent, the appearance of distant metastases was seen in 22
(66.7%) patients during follow-up. The most common loca-
tion of distant metastasis was the lungs (64.0%), followed by
bone (12.0%) and liver (12.0%). Information on the exact
locations of metastases was not available in three (12.0%)
patients. The mean interval for the detection of distant metas-
tases was 43 months (range, 1–156 months). For the group
treated with curative intent, the 5-year Kaplan-Meier estimates
for OS and DSS were 69.7 and 78.9%, respectively, and 10-
year OS and DSS rates were 42.0 and 51.6%, respectively.
Tclasses 2–4 and disease stages II–IVwere associated with
poorer survival. No patients with T class 1 and stage I disease
died of cancer (Fig. 3). In contrast, half of T classes 2–4 and
stages II–IV patients died of cancer. Four patients had neck
metastasis at presentation and this was associated with poorer
OS and DSS, but not with DFS. Female gender and age < 65
were associated with better OS but not with DSS or DFS.
Neural invasion was associated with poorer DFS (Table 3).
However, neural invasion was not associated with the rate of
local or locoregional recurrent disease. Appearance of distant
metastases during follow-up was associated with poorer OS
and DSS. Appearance of locoregional lymph node metastases
was associated with poorer DSS but not poorer OS (Table 3).
The solid growth pattern did not affect survival.
Patients with only 
locoregional 
recurrence (n=3) 
AWD (n=2, 41-51 mo) 
DOD (n=1, 29 mo) 
Patients with curative 
treatment intent 
(n=64) 
Patients with no 
recurrences (n=33)  
NED (n=24, 1-207 mo)   
DOD (n=3, 4-187 mo) 
DOC (n=6, 21-87 mo) 
Patients with recurrence 
at the primary site and 
distant metastasis (n=5) 
DOD (15-102 mo) 
Status at the end of 
the follow-up 
NED (n=24) 
AWD (n= 6) 
DOD (n=24) 
DOC (n= 9) 
N/A (n=1) 
Patients with only distant 
metastasis (n=14) 
AWD (n=3, 72-149 mo) 
DOD (n=9, 4-183 mo) 
DOC (n=1, 71 mo) 
N/A (n=1, 69 mo) 
Patients with distant 
metastasis (n=22)  
AWD (n=3, 72-149 mo) 
DOD (n=17, 4-183 mo) 
DOC (n=1, 71 mo) 
N/A (n=1, 69 mo)
Patients with 
locoregional recurrence 
and distant metastasis    
(n=3) 
DOD (100 mo)
Patients with regional 
recurrence and distant 
metastasis (n=2) 
DOD (34-42 mo) 
Patients with 
recurrences only at 
the primary site (n=8) 
AWD (n=1, 110 mo) 
DOD (n= 4, 35-143 mo) 
DOC (n= 3, 22-128 mo) 
Total number of 
patients assessed in 
the study (n=68)
Fig. 1 Flowchart presenting the
patient series. NED no evidence
of disease, AWD alive with
disease, DOD dead of disease,
DOC dead of other cause,N/A not
available, mo month
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In multivariable Cox regression analysis, male gender,
age > 65 years, T classes 2–4, stages II–IV, and neck metas-
tases at presentation (N+) were associated with poorer OS.
T classes 2–4 and stages II–IV were independently
associated with poorer DFS, but neural invasion did not re-
main significant in multivariable analysis (Table 4).
Patients with stage I disease had a significantly better prog-
nosis and survival than those with stages II, III, and IV dis-
ease. Even with disease failures, none of the stage I patients
died of ACC. It is noteworthy that survival of stage II patients
was significantly poorer than that of stage I patients, even
though the treatment did not differ significantly.
Patients with stage I tumours
Sixteen patients had stage I disease. Three (18.8%) of these
patients experienced disease failure; two local and one distant.
Both patients with local failure had their primary tumour in the
ear canal. The distant failure and one of the local failures
appeared within 5 years. During follow-up, only one patient
with local disease failure died; this was however due to causes
other than ACC. Altogether, ten patients were alive with no
evidence of disease and two with disease at the end of the
follow-up (range, 36–204 months). Four patients died due to
causes other than ACC.
Table 3 OS, DSS, and DFS results of Cox regression analysis
OS DSS DFS
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
T classes T2–4 vs. T1 4.72 (1.60–13.92) 0.005 <0.001* 8.59 (2.46–30.02) 0.001
Neck disease N+ vs. N0 7.37 (1.93–28.09) 0.003 <0.001 2.45 (0.56–10.79) 0.237
Stages II–IV vs. I 3.59 (1.23–10.47) 0.019 <0.001* 9.79 (2.27–42.26) 0.002
Male vs. female 2.32 (1.16–4.65) 0.018 0.087 1.93 (0.95–3.92) 0.070
Age >65 vs. <65 years 3.07 (1.39–6.75) 0.005 0.060 1.46 (0.67–3.19) 0.341
Neural invasion vs. no neural invasion 1.37 (0.60–3.13) 0.456 0.163 3.72 (1.28–10.80) 0.016
Early metastasis vs. no metastasis 4.65 (1.96–11.00) <0.001 20.14 (4.39–92.42) <0.001
Late metastasis vs. no metastasis 1.91 (0.69–5.31) 0.216 5.07 (0.97–26.44) 0.054
Primary metastasis 1.97 (0.98–3.93) 0.056 2.32 (1.03–5.21) 0.042
Regional metastasis 2.50 (0.85–7.36) 0.096 3.81 (1.24–11.77) 0.020
Distant metastasis 2.55 (1.26–5.16) 0.009 4.91 (1.93–12.46) 0.001
OS overall survival, DSS disease-specific survival, DFS disease-free survival, HR hazard ratio, CI confidence interval
*Log-rank test. No patients with T class 1 and stage I disease died due to disease. Log-rank p values were thus used instead of HR with DSS
Fig. 2 Disease-specific survival of 64 patients treated with curative intent
for minor salivary gland adenoid cystic carcinoma (no recurrence group,
early-recurrence group (<5 years), and late-recurrence group (>5 years))
Fig. 3 Disease-specific survival of 64 patients treated with curative intent
for minor salivary gland adenoid cystic carcinoma (stage I vs. stages II–IV)
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Patients with stage II tumours
Twelve patients had stage II disease; eight (66.7%) of these
patients had disease failure. All cases in this group had their
primary tumour located in the oral cavity. Five (62.5%) pa-
tients had disease failure within 5 years and three (37.5%)
after 5 years. At the end of follow-up, four patients were alive
with no evidence of disease, two patients were alive with
disease, five had died due to disease, and one died due to other
causes.
Patients with stages III and IV tumours
Seven patients had stage III disease; four (57.0%) of these
patients experienced disease failure. Three (75.0%) patients
developed metastatic disease within 5 years and one (25.0%)
after 5 years. All patients with disease failure died due to the
disease (range, 4–58 months) and the remainder were alive
with no evidence of disease.
Twenty patients had stage IV disease; 14 (70.0%) of these
patients experienced disease failure. Twelve (85.7%) disease
failures appeared within 5 years and two (14.3%) after 5 years.
Twelve patients died due to the disease (range, 13–
143 months), and one patient was lost to follow-up.
Discussion
To characterize the behaviour and prognosis of MiSG ACC,
we reviewed retrospective cases of 68 MiSG ACC patients
treated between 1974 and 2012 in the Helsinki University
Hospital region. According to our study, patients with stage
I disease had good prognosis during follow-up and none died
of ACC. On the contrary, advanced T class and advanced
stage correlated negatively with OS, DSS, and DFS.
Our group recently reported a similar investigation on the
ACC behavioural pattern inMaSGs [1]. Accordingly, wewere
able to compare these results between MiSGs and MaSGs.
Only a few studies have reported separately the outcome of
ACC in MiSGs and MaSGs [9, 11, 13–17, 19, 20] or com-
pared ACCs in these different locations [21, 22].
In the present study on ACCs in MiSGs, the most common
tumour location was the oral cavity (60%), with palate (49%)
as the most frequent site as reported before [9, 13, 15, 16].
Among palatal tumours, the stage distribution was constant
with slightly more advanced tumours (Table 2). In other
intraoral sites, however, the tumours tended to be less ad-
vanced. On the contrary, in the series by Shum et al., palatal
ACCs were predominantly of advanced T3–T4 classes (90%)
[17]. Detection of palatal tumours may be clinically difficult
compared to other intraoral sites, which might lead to diag-
nostic delay and allow extensive neoplasm infiltration conse-
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noteworthy in our series that ACCs of the nasopharynx and
paranasal sinuses were all of advanced stage, although the
number of these cases was limited. Furthermore, according
to previous studies, ACCs of the paranasal sinuses are usually
diagnosed late and the tumours are more advanced (T3–T4)
[23–25]. It is possible that the nasopharynx and paranasal
sinuses harbour tumour growth without early symptoms.
In previous studies, ACC has shown female predominance [9,
11, 13], which was also seen in our study (female to male ratio of
1.35). However, our previous study on MaSGs showed male
predominance [1]. In the current study, female gender was asso-
ciated with better OS, which may also reflect the higher life
expectancy of women in general. On the other hand, a large
series of head and neck ACC by Ellington et al. comprising
1754 MaSGs, 1117 oral cavity MiSGs, and 138 neck and phar-
ynx ACCs showed a better prognosis for females [21].
Contrary to our study, earlier reports have not emphasized a
good prognosis for stage I tumours in general, although sim-
ilar findings for MiSG ACCs have also been reported. Mücke
et al. did not find significant differences between stages I and
II tumours, and other studies have also considered the behav-
iour of stage II tumours to be less aggressive [9, 15, 16].
DeAngelis et al. showed that T class was the only factor af-
fecting survival, whereas Mücke et al. and Bianchi et al. both
reported that T and N classes and stage affected survival [9,
15, 16]. In our study, Tclasses 2–4 and stages II–IV correlated
negatively with OS, DSS, and DFS. The present results high-
light the favourable survival of patients with stage I disease.
For instance, none of the patients with a stage I tumour died
due to the disease. The only treatment failures in this patient
group occurred in patients with a tumour in the ear or in the
oropharynx. Patients with an oral cavity ACC were free of
disease failures. Disease-free surgical margins are probably
easier to achieve for smaller tumours in the oral cavity than
in the oropharynx or in the ear, which have a more complex
anatomy. Both of the present stage I patients with ACC in the
ear showed local disease failures, which highlights the com-
plexity of surgical anatomy. On the other hand, two other
patients with advanced stage ACC in the ear did not suffer
from disease failures but were also treated more aggressively
with surgery combined with radiotherapy. It might be feasible
to consider more aggressive treatment also for stage I patients
with ACC in this challenging location. According to our re-
sults, stage II disease in the oral cavity presents with poor
outcome and with a high percentage of disease failures
(67%). Considering these observations, patients with stage II
ACC might benefit from more intensive treatment modalities.
Similarly to MiSGs, advanced T class, N class, and advanced
stage in MaSGs also had a negative effect on survival [1].
A well-known feature of ACC is neurotropism, which re-
mains controversial considering that ACC metastasizes pri-
marily haematogenously [26]. Neural invasion did not affect
survival of MaSG ACC patients [1], but for the MiSG ACC
patients in the present study, neural invasion had a negative
effect on DFS. In addition, neural invasion was not associated
with the rate of either local, regional, or locoregional recur-
rences. Contrary to our findings, some studies have reported
that perineural invasion affects treatment outcome of both
MiSG and MaSG ACCs [14, 24, 27].
The growth pattern did not have an effect on survival. A
solid pattern is related to poorer survival. According to the
WHO, tumours with more than 30% of solid pattern have
more aggressive behaviour [2, 18]. With MaSG, there was a
slightly negative trend on survival but no statistically signifi-
cant correlation was observed [1].
In both MiSG and MaSG, disease failures appearing within
5 years of the primary diagnosis significantly influenced OS and
DSS. Primary and locoregional metastases negatively affected
DSS in MiSGs but not in MaSGs. Distant metastases affected
OS and DSS in both MiSGs and MaSGs. Most of the distant
metastases appeared within 10 years in MiSGs and MaSGs [1].
Ellington et al. comparedMiSG ACC toMaSG ACC and found
decreased survival inMiSGs [21]. In the present study, long-term
survival of MiSG ACC patients was similar to that of the MaSG
ACC patients in our previous study [1].
The limitations of this study include its retrospective na-
ture, which led to a shortage of necessary data on some single
cases. Unfortunately, data concerning surgical margins were
not sufficient enough to produce a reliable statistical assess-
ment. The diagnostic assessment and treatment approach has
also varied slightly during the course of the study. However,
we were able to retrieve follow-up data covering a lengthy
time period for all patients except one. Although our sample
size was limited to only one tertiary-care academic centre, the
number of the cases was large when compared to previous
studies on MiSG ACC.
Conclusions
Patients with stage I ACC seem to have a good prognosis
differing from that of patients with stage II tumours.
Therefore, stage II tumours should be considered as truly ad-
vanced disease, which warrants a more aggressive treatment
approach. As most disease failures tend to appear within ap-
proximately 10 years, we recommend an extended follow-up
time of 10 years for MiSG ACC patients.
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